Alliance for mRNA Medicines

Take a quick minute to learn more about India's first mRNA Therapeutics company (and new AMM member), AAARNA Therapeutics. Interested in becoming a member or learning more about the Alliance? Visit https://mrnamedicines.org/.

AMM congratulates Victor Ambros and Gary Ruvkun on receiving the 2024 Nobel Prize in Physiology or Medicine at yesterday's award ceremony. Their pioneering research and the discovery of microRNAs marked a groundbreaking milestone in science and transformed our understanding of gene regulation. This discovery reshaped modern physiology and paved the way for innovative breakthroughs in medicine and future therapies. The impact of their work will resonate for generations to come.

A heartfelt thank you to all the attendees and presenters who made yesterday's event, Don’t Blame the Messenger(RNA): Combatting the Threat of Misinformation, such a success! We’re especially grateful to our joint hosts, the Foundation for mRNA Medicines and The Johns Hopkins University, and to our event sponsors: Arcturus Therapeutics, Maravai LifeSciences Foundation, and ReCode Therapeutics. Your support and collaboration were invaluable in advancing this important conversation. Stay connected with us! Visit mrnamedicines.org for updates on upcoming events, and if you’re not yet a member, sign up to receive the latest information. Together, we can drive change and fight misinformation!

Exciting insights from the AMM Ascent Conference are now live! This article dives into the action items needed to turn promising mRNA science into real-world impact, as discussed by thought leaders, innovators, and experts at the conference. At AMM, we’re proud to convene the brightest minds to explore how mRNA can revolutionize healthcare. From commercializing this groundbreaking technology to addressing challenges, the discussions that took place at Ascent are shaping the future of medicine.

Take a quick minute to learn more about our new member ARNAV Biotech and Pooja Tiwari, Ph.D. Interested in becoming an AMM member? Visit https://mrnamedicines.org to learn more.

It's been a busy year for AMM. Check out some of the highlights below then visit https://mrnamedicines.org to learn how you can become a member today!

A big thank you to all the sponsors and attendees who made AMM’s 1st Annual Meeting a smashing success. Planning is already underway for next year, so stay tuned for updates. Interested in becoming an AMM member? Visit https://mrnamedicines.org/ to learn more.

Learn from key regulators at AMM ASCENT! We’re thrilled to welcome FDA officials to AMM’s 1st annual meeting next week, including Peter Marks, Director of the Center for Biologics Evaluation and Research, and Julie Tierney, Deputy Center Director, who will share critical insights during our Regulatory Outlook session on Thursday, November 14. We’ll explore the FDA's latest perspectives on regulatory pathways for mRNA technologies, tackling challenges in platform technology, and discussing the future of mRNA-based therapies and vaccines. Don’t miss this opportunity to connect, learn, and collaborate with industry leaders dedicated to advancing the future of mRNA medicine It’s not too late to register! https://lnkd.in/e4JzQMf4

Ariel Kantor, PhD, from ReCode Therapeutics, presented “Selective Organ Targeting (SORT) Lipid Nanoparticle (LNP) Platform for Lung Delivery” at TIDES USA 2024 earlier this year. He also represented AMM at the conference in a plenary panel discussion on “mRNA Therapies - The Next Chapter.” Learn more in TIDES Global: https://lnkd.in/eS8SwYff Dr. Kantor will be a featured panelist in our “Investor Perspectives” discussion at AMM ASCENT, our 1st Annual Meeting, coming up next week in Boston. It's not too late to register! Visit https://lnkd.in/e4JzQMf4

Don't miss our "Investor Perspectives" panel at AMM ASCENT, our first annual meeting. Hear leading institutional investors share their insights and perspectives on what is driving their interest in mRNA technology. Featuring: • Alan Colowick (Matrix Capital Management) • Ariel Kantor, PhD (ReCode Therapeutics) • Irina Margine, Ph.D. (Wellington Management) • Ipsita Smolinski (Capitol Street) • Edward Tenthoff (Piper Sandler) AMM ASCENT begins on Nov. 13 and registration closes soon! Learn more and register today: https://lnkd.in/e4JzQMf4